Analysis of Circulating Tumor Markers in Blood - ALCINA 5

ConditionsCancer Lung Cancer, Non-Small Cell

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorInstitut du Cancer de Montpellier - Val d'Aurelle

About this trial

The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,

18 years old or higher ?

Patient who has provided informed, written, and explicit consent,

Patient affiliated with a French Social Protection System.

Disqualifiers

Pregnant woman and/or breast-feeding,

Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,

Private persons of freedom or under guardianship,

Patient with a history of other invasive cancers within the 5 years preceding inclusion.

Trial design

Design model

Parallel

Treatments tested in this trial

Blood sampling C1
Biological/Vaccine
Blood samples will be collected at four key time points : * baseline (T1), * first scan assessment (T2), * second scan assessment (T3), * and progression (T4).

Treatment groups

620 Participants

are divided into 1 treatment group

Group A: COHORT 1 - CUREOther 1 intervention

Trial outcomes

Primary outcomes

All Cohorts : Study of the feasibility of detecting and/or analysing blood or tissue tumour biomarkers.

Success rate of the detection technique used (the criterion will be detailed according to the biomarker evaluated, in each of the cohorts)

Time frame

10 years

Secondary outcomes

COHORT 1 - CURE : to define a liquid biopsy signature for predicting therapeutic response from samples taken before initiation of immunotherapy (T1).

CTCs-PD-L1+/-, ctDNA, circulating proteins (CPs) and circulating immune cells (CICs) will be measured in accordance with the definitions established in T1.

Time frame

4 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Institut du Cancer de Montpellier - Val d'Aurelle

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: